• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin.

作者信息

Coleman Emily, Panse Gauri, Haldas Jason, Gettinger Scott N, Leventhal Jonathan S

机构信息

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.

出版信息

JAAD Case Rep. 2018 Aug 9;4(7):669-671. doi: 10.1016/j.jdcr.2018.06.022. eCollection 2018 Aug.

DOI:10.1016/j.jdcr.2018.06.022
PMID:30112450
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6091308/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd71/6091308/00d103e720d9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd71/6091308/bf8251e9b132/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd71/6091308/00d103e720d9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd71/6091308/bf8251e9b132/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd71/6091308/00d103e720d9/gr2.jpg

相似文献

1
Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin.在帕博利珠单抗治疗背景下出现的类似毛发红糠疹的红皮病，对阿维A治疗有反应。
JAAD Case Rep. 2018 Aug 9;4(7):669-671. doi: 10.1016/j.jdcr.2018.06.022. eCollection 2018 Aug.
2
Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40.一例毛发红糠疹在阻断白细胞介素-17A 后进展为泛发性红皮病，但在阻断白细胞介素-12/23 p40 后有所改善。
J Dermatol. 2019 Jan;46(1):70-72. doi: 10.1111/1346-8138.14709. Epub 2018 Dec 3.
3
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.乌司奴单抗长期治疗难治性Ⅰ型毛发红糠疹。
J Dermatol Case Rep. 2013 Mar 30;7(1):5-9. doi: 10.3315/jdcr.2013.1127.
4
A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report.一例联合使用阿维A和乌司奴单抗成功治疗的经典型成人毛发红糠疹：病例报告
SAGE Open Med Case Rep. 2022 Apr 19;10:2050313X221093453. doi: 10.1177/2050313X221093453. eCollection 2022.
5
Successful treatment of type I pityriasis rubra pilaris with ixekizumab.用司库奇尤单抗成功治疗Ⅰ型毛发红糠疹。
JAAD Case Rep. 2018 Sep 14;4(8):774-776. doi: 10.1016/j.jdcr.2018.05.006. eCollection 2018 Sep.
6
A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab.一例对阿维A与乌司奴单抗联合治疗有效的难治性毛发红糠疹病例。
Dermatol Online J. 2020 Mar 15;26(3):13030/qt1712g0gm.
7
Recurrent Pityriasis Rubra Pilaris: A Case Report.复发性毛发红糠疹：一例报告
J Cutan Med Surg. 2018 Nov/Dec;22(6):624-626. doi: 10.1177/1203475418775378. Epub 2018 May 13.
8
Late onset pityriasis rubra pilaris type IV treated with low-dose acitretin.低剂量阿维A治疗IV型迟发性毛发红糠疹
Acta Dermatovenerol Alp Pannonica Adriat. 2016;25(1):15-7. doi: 10.15570/actaapa.2016.4.
9
Pityriasis rubra pilaris.红皮病型毛发红糠疹
Dermatol Online J. 2003 Oct;9(4):6.
10
[Pityriasis rubra pilaris].[毛发红糠疹]
Hautarzt. 2004 Oct;55(10):980-3. doi: 10.1007/s00105-004-0811-7.

引用本文的文献

1
Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.免疫检查点抑制剂相关的皮肤不良反应：一篇综述文章。
Curr Oncol. 2022 Apr 18;29(4):2871-2886. doi: 10.3390/curroncol29040234.
2
Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report.帕博利珠单抗治疗肺癌患者时的皮肤不良反应：一例报告。
Exp Ther Med. 2022 Jan;23(1):15. doi: 10.3892/etm.2021.10937. Epub 2021 Oct 29.
3
Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.新型靶向治疗药物的皮肤不良反应——免疫检查点抑制剂和 EGFR 抑制剂。

本文引用的文献

1
Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.白细胞介素 23-辅助性 T 细胞 17 轴作为治疗毛发红糠疹的靶点。
JAMA Dermatol. 2017 Apr 1;153(4):304-308. doi: 10.1001/jamadermatol.2016.5384.
2
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.免疫检查点阻断疗法引发的多种类型皮肤毒性反应。
J Cutan Pathol. 2017 Feb;44(2):158-176. doi: 10.1111/cup.12858. Epub 2016 Dec 21.
3
Anti-PD1-induced psoriasis: a study of 21 patients.抗程序性死亡蛋白1（Anti-PD1）诱导的银屑病：21例患者的研究
J Dtsch Dermatol Ges. 2021 Nov;19(11):1621-1643. doi: 10.1111/ddg.14641.
4
The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes.皮肤免疫相关不良事件的临床和组织病理学特征及其结局
J Clin Med. 2021 Feb 12;10(4):728. doi: 10.3390/jcm10040728.
5
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.免疫检查点抑制剂治疗相关炎症性皮疹：毒性分层的单机构回顾性分析及其对治疗的影响。
J Am Acad Dermatol. 2019 Apr;80(4):990-997. doi: 10.1016/j.jaad.2018.10.062. Epub 2018 Nov 3.
J Eur Acad Dermatol Venereol. 2017 May;31(5):e254-e257. doi: 10.1111/jdv.14011. Epub 2016 Nov 7.
4
Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma.在帕博利珠单抗治疗转移性黑色素瘤期间发生的慢性苔藓样糠疹样药物疹。
JAAD Case Rep. 2016 Aug 17;2(4):343-5. doi: 10.1016/j.jdcr.2016.06.012. eCollection 2016 Jul.
5
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.PD-1 阻断增强了前列腺癌和晚期黑色素瘤患者外周血中的 Th1 和 Th17，抑制了 Th2 反应。
J Immunother. 2012 Feb-Mar;35(2):169-78. doi: 10.1097/CJI.0b013e318247a4e7.